Saliva-based glycated albumin diagnostic kit that DYD is preparing for mass production. Provided by DYD
DYD publicly unveiled for the first time a saliva-based glycated albumin diagnostic kit, which is currently being prepared for mass production, at a corporate briefing held on the 11th. The glycated albumin diagnostic kit revealed on this day is a product that can diagnose diabetes using only saliva tests instead of the conventional blood test method, and it is explained that glycated albumin can be measured in just one minute.
At the briefing, DYD announced plans for mass production of the diagnostic kit. The development of the core component of the diagnostic kit, the semiconductor wafer, has already been completed, and optimization for product mass production has been finalized. A plan for the mass production phase has also been established. Over the next 3 to 4 months, prototype production, performance evaluation, and clinical preparation will commence.
The company signed a business agreement last month with Gangwon Special Self-Governing Province and medical device manufacturer MIJ to establish a bio-semiconductor production base.
The importance of developing diagnostic kits using semiconductors was also mentioned at the briefing. DYD highlighted that using semiconductor wafers in the diagnostic kit eliminates the need for a separate amplification process and offers high applicability of the underlying technology. Additionally, it emphasized that this approach is very advantageous in terms of cost.
Meanwhile, DYD is pursuing approval from the U.S. Food and Drug Administration (FDA) for the saliva-based glycated albumin diagnostic kit. To this end, it recently pursued a business agreement with Montgomery County, Maryland, where the U.S. FDA headquarters is located.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
